Keryx Biopharmaceuticals News

Check below for free stories on KO;KERX;DPS;NBIX;SPN;PEP;CSG;CALD;SYRG;TEVA;VNTV;UBNT;MA;V;TSS;GPN;GDOT;MGI;FLT;HPY;WU;CORR the last two weeks.

Keryx Biopharmaceuticals opened at 7.66 on Wednesday. Keryx Biopharmaceuticals has a 1-year low of $1.36 and a 1-year high of $9.98.

Major drug manufacturers in the U.S., as well as globally, have been facing increasing competition from generic drug makers following the expiration of patents for several blockbuster drugs.

Keryx Biopharmaceuticals presented additional details from its pivotal Phase III study for Zerenex Monday at the World Congress of Nephrology meeting during a lunch presentation.

In today's marketplace, there are many gauges investors can use to track publicly traded companies.

Shares of Keryx Biopharmaceuticals continue to trade within a tight range, but with several catalyzing events approaching, we believe the stock is ready to break out.

With a potential U.S. market for Chronic Kidney Disease and End Stage Renal Disease patients of almost $1bb, based on 5mm CKD patients above age 65, of whom ~50% are in stage 3-5, there is ample opportunity for a few under-appreciated stories focusing on this market to see real traction as we head into 2H/13. I've highlighted a few of the more ... (more)